IN2014DN06850A - - Google Patents

Download PDF

Info

Publication number
IN2014DN06850A
IN2014DN06850A IN6850DEN2014A IN2014DN06850A IN 2014DN06850 A IN2014DN06850 A IN 2014DN06850A IN 6850DEN2014 A IN6850DEN2014 A IN 6850DEN2014A IN 2014DN06850 A IN2014DN06850 A IN 2014DN06850A
Authority
IN
India
Prior art keywords
ch2oh
cooh
carbon atoms
present
invention regards
Prior art date
Application number
Other languages
English (en)
Inventor
Valle Francesco Della
Valle Maria Federica Della
Gabriele Marcolongo
Marzo Vincenzo Di
Salvatore Cuzzocrea
Original Assignee
Epitech Group Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epitech Group Srl filed Critical Epitech Group Srl
Publication of IN2014DN06850A publication Critical patent/IN2014DN06850A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/10—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D263/12—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with radicals containing only hydrogen and carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/10—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/10—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D263/14—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/06—1,3-Oxazines; Hydrogenated 1,3-oxazines not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/08—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D277/10—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
IN6850DEN2014 2012-02-17 2012-02-17 IN2014DN06850A (en URL)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IT2012/000050 WO2013121449A1 (en) 2012-02-17 2012-02-17 Compositions and methods for the modulation of specific amidases for n-acylethanolamines for use in the therapy of inflammatory diseases

Publications (1)

Publication Number Publication Date
IN2014DN06850A true IN2014DN06850A (en URL) 2015-06-26

Family

ID=46000230

Family Applications (1)

Application Number Title Priority Date Filing Date
IN6850DEN2014 IN2014DN06850A (en URL) 2012-02-17 2012-02-17

Country Status (13)

Country Link
US (1) US9512091B2 (en URL)
EP (1) EP2814489B1 (en URL)
JP (1) JP5982016B2 (en URL)
KR (1) KR101854879B1 (en URL)
CN (1) CN104244948B (en URL)
AR (1) AR090066A1 (en URL)
AU (1) AU2012327209B2 (en URL)
CA (1) CA2864259C (en URL)
DK (1) DK2814489T3 (en URL)
ES (1) ES2648188T3 (en URL)
IN (1) IN2014DN06850A (en URL)
PT (1) PT2814489T (en URL)
WO (1) WO2013121449A1 (en URL)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2772252T3 (es) * 2014-03-21 2020-07-07 Epitech Group S P A Preparaciones oftálmicas, intraarticulares o intravesicales que contienen N-acil-etanolaminas
DK2965765T3 (da) 2014-07-08 2019-07-22 Epitech Group S P A Anvendelse af adelmidrol til behandling af epiteldysfunktioner
KR20180044259A (ko) * 2015-06-16 2018-05-02 머독 칠드런스 리서치 인스티튜트 크론병 치료 방법
RU2737893C2 (ru) 2015-08-11 2020-12-04 Айсью Медсинз Б.В. Пэгилированная липидная наночастица с биоактивным липофильным соединением
MY191276A (en) * 2016-10-09 2022-06-13 Shenzhen Eulikan Biotechnology Co Ltd Use of antimicrobial agent combination in preparing composition for vagina, composition for vagina and method for preparing the same
JP7014959B2 (ja) 2017-03-10 2022-02-02 ダイキン工業株式会社 庫内空気調節装置及びそれを備えたコンテナ用冷凍装置
US10143639B2 (en) * 2017-03-22 2018-12-04 William Robert McDaniel Use of adelmidrol and other topical or oral cannabinomimetic or aliamide mast cell inhibitors to treat dermatoheliosis, seborrheic keratoses, and androgenetic alopecia
SG10201802129QA (en) * 2017-07-05 2019-02-27 Frimline Private Ltd A pharmaceutical composition for neuropathic pain
SG10201807034XA (en) 2017-09-05 2019-04-29 Frimline Private Ltd A pharmaceutical composition for improving or preventing progression of Chronic Kidney Disease
EP3574899A1 (en) * 2018-05-28 2019-12-04 Université de Bourgogne Oleic acid derivatives, pharmaceutical composition or food composition comprising said oleic acid derivatives, and their uses
FR3098394B1 (fr) * 2019-07-12 2022-07-08 Expanscience Lab Composition comprenant au moins une oxazoline pour inhiber la croissance de levure du genre Malassezia impliquée notamment dans les croûtes de lait
EP4331577A1 (en) * 2022-08-30 2024-03-06 Unifarco S.p.A. A nutraceutic tablet comprising palmitoylethanolamide

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2368075A (en) * 1943-09-11 1945-01-23 Commercial Solvents Corp Astringent preparations
US2450806A (en) * 1945-12-07 1948-10-05 Gulf Research Development Co Rust preventive chromium compounds and compositions containing them
US2547493A (en) * 1949-12-01 1951-04-03 Rohm & Haas Imido-esters of diels-alder adducts and process for producing same
US2965459A (en) * 1958-03-03 1960-12-20 Standard Oil Co Gasoline containing borated oxazolines
US3389145A (en) * 1965-10-24 1968-06-18 Katz Jacob Fatty oxazoline surfactants and a process for their preparation
US3648847A (en) * 1969-01-07 1972-03-14 Reichhold Chemicals Inc Filter aid conditioners
US3886128A (en) * 1973-10-15 1975-05-27 Commercial Solvents Corp Oxazoline emulsifier in polymerization of styrene and butadiene
US3920567A (en) 1974-12-27 1975-11-18 Exxon Research Engineering Co Novel oxazoline-alkyl acid phosphate adducts useful as ashless antiwear additives
JPS5283321A (en) * 1975-12-27 1977-07-12 Takeshi Tomiyama Method of manufacturing geranyl farnesyl acetate
US4049819A (en) * 1976-02-09 1977-09-20 Imc Chemical Group, Inc. Method of combatting microorganisms employing substituted oxazolines
US4224172A (en) 1978-12-04 1980-09-23 Mobil Oil Corporation Oil-soluble adducts of benzotriazole and oxazolines and lubricant compositions containing same
US4477384A (en) * 1981-02-20 1984-10-16 The United States Of America As Represented By The Secretary Of Agriculture Preparation of α-substituted acrylic acids
GB2187726B (en) * 1986-03-14 1989-11-15 Ici Plc Solid explosive composition.
US4876249A (en) * 1987-01-12 1989-10-24 Rajadhyaksha Vithal J Compositions and method comprising heterocyclic compounds containing two heteroatoms
DE3710516A1 (de) * 1987-03-30 1988-10-20 Henkel Kgaa Verfahren zur herstellung von 2-benzylfettsaeuren
NZ226043A (en) * 1987-09-23 1991-05-28 Ici Australia Operations Explosive composition: ammonium nitrate prills
DE3824982A1 (de) * 1987-11-10 1989-05-18 Henkel Kgaa 2-(11-hydroxy-8-heptadecenyl- oder 11,8- bzw. 11,9-heptadecadienyl)oxazolin, sowie verfahren zur herstellung gegebenenfalls substituierter hoeherer 2-(alkyl- bzw. alkenyl)-oxazoline
JPH0747636B2 (ja) * 1988-12-05 1995-05-24 東レ株式会社 熱可塑性ポリアミド樹脂組成物
DE3914155A1 (de) * 1989-04-28 1990-10-31 Henkel Kgaa Verfahren zur herstellung von 5,6-dihydro-4h-1,3-oxazinen
DE4104789A1 (de) * 1991-02-16 1992-08-20 Henkel Kgaa Cyclische polyiminoether
DE4229020A1 (de) * 1992-09-03 1994-03-10 Henkel Kgaa Verfahren zur Herstellung von þ-Alkanoylaminoalkyl-substituierten quartären Ammoniumsalzen
US5698017A (en) * 1996-09-27 1997-12-16 Xerox Corporation Oxazoline hot melt ink compositions
US6462054B1 (en) 2000-03-27 2002-10-08 The Scripps Research Institute Inhibitors of fatty acid amide hydrolase
US6706674B2 (en) * 2001-01-17 2004-03-16 The Andrew Jergens Company Nonaqueous hair styling composition and method of use
FR2834216B1 (fr) 2001-12-27 2004-04-30 Pharmascience Lab Composition cosmetique ou pharmaceutique comprenant au moins une oxazoline pour inhiber la migration des cellules de langerhans, et ses utilisations
MXPA05003762A (es) * 2002-10-08 2005-07-22 Scripps Research Inst Inhibidores de hidrolasa de amida de acido graso.
FR2885128B1 (fr) * 2005-04-27 2007-07-06 Expanscience Laboratoires Sa Composition cosmetique a visee depigmentante ou eclaircissante comprenant au moins une oxazoline, a titre de principe actif depigmentant ou eclaircissant
US7905361B2 (en) * 2007-02-05 2011-03-15 Dow Global Technologies Llc Modified polyamide membrane
US20110184026A1 (en) 2008-06-19 2011-07-28 Boger Dale L C4-substituted alpha-keto oxazoles
WO2011085216A2 (en) 2010-01-08 2011-07-14 Ironwood Pharmaceuticals, Inc. Use of faah inhibitors for treating parkinson's disease and restless legs syndrome

Also Published As

Publication number Publication date
CN104244948A (zh) 2014-12-24
EP2814489B1 (en) 2017-08-23
US20150057269A1 (en) 2015-02-26
WO2013121449A8 (en) 2013-12-12
AU2012327209A1 (en) 2013-10-31
DK2814489T3 (en) 2017-10-30
EP2814489A1 (en) 2014-12-24
ES2648188T3 (es) 2017-12-29
US9512091B2 (en) 2016-12-06
CA2864259A1 (en) 2013-08-22
CN104244948B (zh) 2016-11-16
PT2814489T (pt) 2017-10-23
AR090066A1 (es) 2014-10-15
WO2013121449A1 (en) 2013-08-22
KR101854879B1 (ko) 2018-05-04
JP5982016B2 (ja) 2016-08-31
JP2015511239A (ja) 2015-04-16
AU2012327209A8 (en) 2015-01-22
AU2012327209B2 (en) 2016-05-19
CA2864259C (en) 2019-06-11
KR20140147819A (ko) 2014-12-30

Similar Documents

Publication Publication Date Title
IN2014DN06850A (en URL)
RS53679B1 (en) FURAZANOBENZIMIDAZOLES AS PROGRAMS FOR THE TREATMENT OF NEOPLASTIC OR AUTOIMMUNE DISEASES
MY191912A (en) Estolide compositions exhibiting high oxidative stability
JO3221B1 (ar) مركبات حمض داي ميثيل - بنزويك مفيدة لعلاج الحالات الالتهابية
IN2014DN03483A (en URL)
MY155133A (en) Compounds having crth2 antagonist activity
IN2014MN01521A (en URL)
AR086958A1 (es) Antagonistas de trpv4
NZ592228A (en) Compounds and their salts specific to the PPAR receptors and the EGF receptors and their use in the medical field
MX350720B (es) Metodos de tratamiento usando compuestos lipidos.
JP2017526786A5 (en URL)
AR085920A1 (es) Derivados benzimidazolicos utiles como agentes antitumorales y composiciones farmaceuticas que los contienen
MX2016014239A (es) Composicion limpiadora.
WO2012153825A3 (en) Skin external preparation and method of producing same
AR080249A1 (es) Compuestos en calidad de antagonistas de bradiquinina-b1
IN2014MN00411A (en URL)
IN2014DN02947A (en URL)
EA201590315A1 (ru) Средства и способ лечения солидных опухолей
TW201129532A (en) Salt and photoresist composition containing the same
IN2014MN00850A (en URL)
BR112014015430A8 (pt) formulação oftálmica
MX2016010952A (es) Nuevos derivados de cannabigerol.
AR077429A1 (es) Compuestos hidroxiasenapina sus derivados y composiciones farmaceuticas que comprenden los mismos
MX2013009386A (es) Nuevos compuestos de azaespirodecanona.
IN2012DN01251A (en URL)